domagrozumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
domagrozumab

GtoPdb Ligand ID: 9096

Synonyms: clone OGD1.0.0 [2] | PF-06252616 | PF06252616

Compound class: Antibody

Comment: Domagrozumab is a humanized monoclonal antibody targeting myostatin (MSTN), being investigated for potential therapeutic action in muscle wasting diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with sequences claimed in patent US8992913 [2].

References
1. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature, 420 (6914): 418-21. [PMID:12459784]
2. Mader MM, Apgar JR, Parris KD. (2015) Antagonist antibodies against GDF-8 and uses therefor. Patent number: US8992913 B2. Assignee: Pfizer Inc.. Priority date: 15/06/2012. Publication date: 31/03/2015.

References

1. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. (2002)
Functional improvement of dystrophic muscle by myostatin blockade.
Nature, 420 (6914): 418-21. [PMID:12459784]

2. Mader MM, Apgar JR, Parris KD. (2015)
Antagonist antibodies against GDF-8 and uses therefor.
Patent number: US8992913 B2. Assignee: Pfizer Inc.. Priority date: 15/06/2012. Publication date: 31/03/2015.